csm_Was_ist_Diabetes_509a0e65e9.jpg

DIABETES

Develop more effective treatment and prevention strategies

Studies have proved InBody DSM-BIA body composition analyzers are an effective tool for managing patients’ diabetic risks and symptoms. InBody products do not rely on empirical data, therefore, medical professionals can be certain the outputs generated by the device accurately reflect changes happening in the patient.

In less than 60 seconds, an InBody Test provides a comprehensive Result Sheet to help professionals:

  • Obtain objective measurements of muscle, fat, and visceral fat to assess disease risk and obesity

  • Monitor outcomes of interventions aimed to improve glycemic control and prevent worsening of complications related to diabetes

  • Detect fluid imbalances resulting from inflammation

Identify frailty risk and sarcopenia

inbody-770-smi-1310x1536 (1).png

Diabetics patients tend to lose muscle mass. This loss in muscle mass tends to increase with the duration of diabetes, thus leading to the development of other conditions, including sarcopenia. InBody provides a skeletal muscle index (SMI) output that allows for the monitoring of skeletal muscle mass to help prevent or identify sarcopenia.

It is well known that skeletal muscle mass is important to monitor for diabetics. This results from glucose not being utilized to assist in building muscle as well as decreased physical activity causing muscle mass to deplete. This can also cause increased fatigue and further reduction of physical activity and function. The resulting decrease in muscle mass experienced by these patients increases the risk for other conditions such as sarcopenia and impaired mobility.

Sarcopenia is the loss of skeletal muscle mass, which decreases functional mobility and quality of life and increases risk of hospitalization and mortality. Sarcopenia is often associated with aging; however, it can occur in a variety of populations due to sedentary behavior or even disease. The SMI is used in order to assess and conveniently monitor skeletal muscle mass to aid in the diagnosis of sarcopenia. SMI is calculated as the sum of appendicular lean mass, normalized to height.

With the prevalence of muscle loss in diabetics and the association diabetes and sarcopenia, monitoring risk for sarcopenia in diabetics is imperative. Using the SMI output on InBody results will allow medical professionals to identify the risk of sarcopenia in easily identify increased frailty risk and promote education and intervention.

Are you wondering if a professional InBody device is right for you? We partner you with an InBody specialist that understands your industry and unique needs.